Achillion Pharmaceuticals Inc (NASDAQ:ACHN) recently announced that its partner, Janssen, has fully enrolled its 365-patient Phase IIb trial testing the triple combination of ALS-022335, simeprevir and odalasvir (together known as JNJ-4178) to treat hepatitis C patients, with results expected in H217. Importantly, the trial will be testing six- and eight-week treatment durations (the current standard treatment duration is 8-12 weeks). Achillion also recently initiated patient dosing in a Phase II trial of ACH-4471 in treatment naïve PNH patients.
Janssen triple combo Phase IIb fully enrolled
Following positive data in which the combination of ALS-022335, simeprevir and odalasvir for the treatment of genotype 1 hepatitis C virus (HCV) achieved a 100% sustained virologic response at 12 weeks post treatment (SVR12) in all patients (n=60) for both six- and eight-week treatment durations, Janssen decided to move forward with a 365-patient Phase IIb, which is now fully enrolled. Data is expected in H217 and advancement to Phase III is currently expected in 2018 (previously estimated to be 2017).
To read the entire report Please click on the pdf File Below